Arvinas, Inc.
A biotech company pioneering a new kind of medicine that works like a cellular "molecular matchmaker": instead of blocking disease-causing proteins, its PROTAC drugs tag them for the cell's own garbage disposal (the proteasome) to shred and recycle. Founded in 2013 by Yale professor Craig Crews, Arvinas grew out of his earlier company Proteolix, and in 2026 its breast-cancer therapy vepdegestrant, developed with Pfizer, became the first FDA-approved PROTAC treatment. It focuses on cancer and neurological disease.
Sold 318.2K
Granted 418.1K · Sold 123.7K
Granted 18.4K · Sold 662.1K
Granted 160.5K · Sold 21.1K
Granted 223.3K · Sold 31.9K
Granted 215.1K · Sold 27.7K
Granted 58.7K · Sold 35.0K
Granted 169.7K · Sold 27.2K
Granted 136.1K · Sold 52.6K
Granted 73.9K · Bought 50.0K · Sold 41.9K
Granted 41.6K
Granted 86.4K · Sold 24.3K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 40.6K · Sold 5.9K
Granted 30.2K
Granted 26.0K
Granted 4.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shannon Timothy MDirector · 18 transactions | -14.5% | 1.76Mas of Sep 2021 | — | — | 318.2K |
| Houston John GDirector · 19 transactions | +33.4% | 1.12M | 418.1K | — | 123.7K |
| Ratcliffe LiamDirector · 41 transactions | — | 914.2Kas of Dec 2021 | 18.4K | — | 662.1K |
| Teel RandyPresident and CEO, Director · 7 transactions | — | 285.0K | 160.5K | — | 21.1K |
| Berkowitz NoahChief Medical Officer · 8 transactions | — | 191.4K | 223.3K | — | 31.9K |
| Saik AndrewChief Financial Officer · 8 transactions | — | 187.4K | 215.1K | — | 27.7K |
| Cassidy Sean AChief Financial Officer · 10 transactions | +3.7% | 181.9Kas of Feb 2024 | 58.7K | — | 35.0K |
| Cacace Angela MChief Scientific Officer · 12 transactions | — | 180.4K | 169.7K | — | 27.2K |
| Taylor IanPresident, R&D · 25 transactions | +104.4% | 160.8Kas of Feb 2025 | 136.1K | — | 52.6K |
| Morrison BriggsDirector · 15 transactions | +277.9% | 111.5K | 73.9K | 50.0K | 41.9K |
| Kennedy Edward Moore Jr.Director · 4 transactions | — | 84.3K | 41.6K | — | — |
| Peck RonaldChief Medical Officer · 11 transactions | +898% | 67.5Kas of Feb 2024 | 86.4K | — | 24.3K |
| Bain LindaDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Cunningham EverettDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Norwalk Leslie VDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Smaldone Alsup LaurieDirector · 4 transactions | — | 41.6K | 41.6K | — | — |
| Loomis David KVP, Chief Accounting Officer · 11 transactions | — | 40.2K | 40.6K | — | 5.9K |
| Agarwal SunilDirector · 3 transactions | — | 30.2Kas of Jun 2025 | 30.2K | — | — |
| Young John DDirector · 3 transactions | — | 26.0Kas of Jun 2025 | 26.0K | — | — |
| Dixon Wendy LDirector · 1 transaction | +82.4% | 9.1Kas of Jun 2023 | 4.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.32M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.